OMG and myeloid sarcoma: In this paper, we review recent evidence regarding human leukocyte antigen (HLA) genotyping and myelin oligodendrocyte glycoprotein (MOG) antibodies—the two most important candidate biomarkers for early-onset MS—as well as their potential application in the diagnosis and treatment of MS.